Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
6.25
-0.20 (-3.10%)
Apr 29, 2026, 11:15 AM EDT - Market open
Harvard Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 86.55 | 94.14 | 112.25 | 113.34 | 118.9 | Upgrade
|
| Revenue Growth (YoY) | -8.06% | -16.14% | -0.96% | -4.68% | 16.46% | Upgrade
|
| Cost of Revenue | 36.64 | 39.33 | 45.86 | 51.05 | 51.25 | Upgrade
|
| Gross Profit | 49.91 | 54.81 | 66.39 | 62.29 | 67.65 | Upgrade
|
| Selling, General & Admin | 35.56 | 43.52 | 46.61 | 49.03 | 47.32 | Upgrade
|
| Research & Development | 8.83 | 10.41 | 11.76 | 12.33 | 10.8 | Upgrade
|
| Amortization of Goodwill & Intangibles | 4.03 | 5.26 | 5.53 | 6.12 | 5.84 | Upgrade
|
| Other Operating Expenses | - | 0.35 | - | - | - | Upgrade
|
| Operating Expenses | 48.41 | 59.53 | 63.9 | 67.48 | 63.96 | Upgrade
|
| Operating Income | 1.5 | -4.72 | 2.5 | -5.19 | 3.69 | Upgrade
|
| Interest Expense | -4.92 | -3.54 | -3.59 | -2.55 | -1.54 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.29 | -0.51 | -0.44 | 0.72 | -1.02 | Upgrade
|
| EBT Excluding Unusual Items | -8.71 | -8.77 | -1.53 | -7.02 | 1.14 | Upgrade
|
| Merger & Restructuring Charges | -0.19 | -0.84 | -0.39 | -2.39 | -1.28 | Upgrade
|
| Impairment of Goodwill | -47.95 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.59 | -0.63 | - | - | Upgrade
|
| Legal Settlements | - | - | - | 0.23 | - | Upgrade
|
| Other Unusual Items | -0.54 | -0.47 | - | - | - | Upgrade
|
| Pretax Income | -57.39 | -11.67 | -2.56 | -9.18 | -0.14 | Upgrade
|
| Income Tax Expense | -0.69 | 0.74 | 0.86 | 0.34 | 0.15 | Upgrade
|
| Earnings From Continuing Operations | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 | Upgrade
|
| Net Income | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 | Upgrade
|
| Net Income to Common | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 1.96% | 2.64% | 2.43% | 2.65% | 4.41% | Upgrade
|
| EPS (Basic) | -12.77 | -2.85 | -0.81 | -2.30 | -0.07 | Upgrade
|
| EPS (Diluted) | -12.80 | -2.85 | -0.81 | -2.30 | -0.10 | Upgrade
|
| Free Cash Flow | 5.47 | -1.2 | 12.24 | -0.44 | 0.07 | Upgrade
|
| Free Cash Flow Per Share | 1.23 | -0.28 | 2.88 | -0.11 | 0.02 | Upgrade
|
| Gross Margin | 57.67% | 58.22% | 59.15% | 54.96% | 56.90% | Upgrade
|
| Operating Margin | 1.73% | -5.01% | 2.22% | -4.58% | 3.10% | Upgrade
|
| Profit Margin | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% | Upgrade
|
| Free Cash Flow Margin | 6.32% | -1.28% | 10.90% | -0.39% | 0.06% | Upgrade
|
| EBITDA | 7.44 | 2.44 | 9.49 | 2.38 | 11.31 | Upgrade
|
| EBITDA Margin | 8.60% | 2.59% | 8.46% | 2.10% | 9.51% | Upgrade
|
| D&A For EBITDA | 5.95 | 7.16 | 7 | 7.58 | 7.62 | Upgrade
|
| EBIT | 1.5 | -4.72 | 2.5 | -5.19 | 3.69 | Upgrade
|
| EBIT Margin | 1.73% | -5.01% | 2.22% | -4.58% | 3.10% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.